Asking Questions
If you wish to submit a question, you may ask a question before the meeting beginning at 9:00 am Eastern Time, on April 20, 2020, and until 11:59 pm
Eastern Time, on May 13, 2020. To submit a question, you may log into www.proxyvote.com and enter your 16-digit control number. Once past the login screen, click on Question for
Management, type in your question, and click Submit. Only questions pertinent to meeting matters will be answered during the meeting, subject to time constraints.
Voting Shares at the Virtual Meeting
If you have not
voted your shares prior to the meeting, you will be able to vote your shares electronically at the 2020 Annual Meeting by clicking Vote Here on the meeting website. Whether or not you plan to attend the meeting, you are encouraged to
vote your shares prior to the meeting by one of the methods described in the proxy materials you previously received.
The proxy materials you previously
received may continue to be used to vote your shares in connection with the meeting. The previously distributed proxy materials will not be updated to reflect the change to a virtual format or change in time. If you have already voted, you do not
need to vote again.
About INOVIO
INOVIO is a
biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infectious diseases. INOVIO is the first and only company to have
clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to produce a robust and tolerable immune response. Specifically, INOVIOs lead candidate
VGX-3100, currently in Phase 3 trials for precancerous cervical dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical trial. High-risk HPV is responsible for 70% of cervical cancer,
90% of anal cancer, and 69% of vulvar cancer. Also in development are programs targeting HPV-related cancers and a rare HPV-related disease, recurrent respiratory
papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded infectious disease DNA vaccine development
programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses associated with MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill &
Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA)/DOD, GeneOne Life Science/VGXI, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer
Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Plumbline Life Sciences, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The
Wistar Institute. INOVIO also is a proud recipient of 2020 Women on Boards W designation recognizing companies with more than 20% women on their board of directors. For more information, visit www.inovio.com.
CONTACTS:
Investors:
|
Ben Matone, 484-362-0076,
ben.matone@inovio.com
|
Media:
|
Jeff Richardson, 267-440-4211,
jrichardson@inovio.com
|
|
|
Important Notice Regarding the Availability of Proxy Materials for the 2020 Annual Meeting of Stockholders
to be held on May 14, 2020 virtually via live audio-only webcast at
www.virtualshareholdermeeting.com/INO2020.
The Proxy Statement and our Annual Report on Form 10-K for the fiscal year ended December 31,
2019, as
filed with the Securities and Exchange Commission, are available at www.proxyvote.com.
|
April 15, 2020
By order of the Board of Directors
J. Joseph Kim, Ph.D.
Chief
Executive Officer